Monte Rosa Therapeutics, Inc. (GLUE) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$12.50

From 52W high−52.07%

Volume1.56M

Market cap$1.03B

P/E (TTM)—

P/S (TTM)36.0x

Div yield—

Key dataSep 18, 2026

Open

$12.50

From 52W high

−52.07%

Volume

1.56M

Market cap

$1.03B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.9x

P/E (TTM)

—

RSI (14)

28.2

MomentumView details →

1D Return

−3.73%

YTD Return

−21.34%

SummaryUpdated Jun 1, 2026

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Boston, Massachusetts. The company went public in June 2021 and specializes in developing innovative small molecule precision medicines that harness the body's natural protein degradation systems to treat cancer and immune-mediated diseases. Monte Rosa has emerged as a pioneer in the molecular glue degrader space, with multiple programs advancing through clinical development across oncology and immunology therapeutic areas.

Ask drillr about Monte Rosa Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.9x

EV/Sales

15.7x

P/S (TTM)

36.0x

P/B (TTM)

2.1x

ProfitabilityView details →

Gross Margin

92.94%

Net Margin

−560.85%

EBITDA Margin

−542.51%

ROE (TTM)

−33.06%

ROA (TTM)

−23.15%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

−83.86%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+63.54%

EPS CAGR 3Y

+39.80%

EBITDA YoY

—

MomentumView details →

1D Return

−3.73%

YTD Return

−21.34%

1Y Return

+94.84%

RSI (14)

28.2

vs 50D SMA

−28.04%

vs 200D SMA

−33.15%

Capital & dividendView details →

Debt/Equity

0.08x

Current Ratio

9.52x

Quick Ratio

9.52x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.43

EPS Surprise

−13.02%

Beats (12Q)

8/12

Next Q EPS Est

−$0.24

Avg Surprise (4Q)

−27.99%

Rev Surprise

−28.46%

Financials snapshotView financials →

Revenue (TTM)

28.73M

Net Income (TTM)

−161.12M

Op. CF (TTM)

−61.44M

Next earningsNov 5, 2026 →

Latest newsMore news →

Monte Rosa Therapeutics reported its Q2 2026 financial results, with collaboration revenue of $9.0 million, a net loss of $43.4 million, and cash and investments of $626.0 million as of June 30, 2026.45d ago

Similar companies

Maravai LifeSciences Holdings, Inc.MRVI Kura Oncology, Inc.KURA Cloudbreak Pharma Inc.02592.HK MoonLake ImmunotherapeuticsMLTX Janux Therapeutics, Inc.JANX Adlai Nortye Ltd.ANL Find similar companies →

Latest newsMore news →